Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT05065190 |
| Consolidated Lead Sponsor | Boehringer Ingelheim |
| Therapeutic Condition Cohort | Rare Genetic, Women's Health, and Other |
| Clinical Trial Phase | Phase III |
| Overall Recruitment Status | COMPLETED |
| Registered Enrollment | 81 participants (ACTUAL) |
| Registered Start Date | 2021-11-25 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| China-Japan Friendship Hospital | Beijing, China | Open Hospital Dossier -> |
| The Second Hospital of Jilin University | Changchun, China | Open Hospital Dossier -> |
| Xiangya Hospital Central South University | Changsha, China | Open Hospital Dossier -> |
| Hangzhou First People's Hospital | Hangzhou, China | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.